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High clearance continuous renal replacement therapy with a SLOW CONTINUOUS DIALYSIS
modified dialysis machine. Recent studies suggest that the dial-
We used a modified dialysis machine, the 2008H (Fre-ysis dose significantly affects survival in acute renal failure
senius Medical Care, Lexington, MA, USA), for SCD.(ARF) patients and that bicarbonate dialysate improves acid-
base balance during continuous renal replacement therapy Special software was developed to permit dialysate flow
(CRRT). These data inspired us to use slow continuous dialysis rates down to 100 ml/min (range 100 to 800 ml/min)
(SCD) in the treatment of ARF. SCD is defined by the follow- while maintaining temperature control.
ing parameters: (a) blood flow (QB) 5 100 to 200 ml/min, (b) Patients were treated continuously with a blood flowdialysate flow (QD) 5 100 to 300 ml/min, (c) the use of a
(QB) of 100 to 200 ml/min and a dialysate flow (QD)modified hemodialysis machine with controlled ultrafiltration
and online production of bicarbonate-based dialysate, and (d) of 100 ml/min. F40 or AV400S polysulfone hemofilters
continuous or extended daily treatment for 8 to 24 hours. SCD (Fresenius Medical Care), each with surface areas of 0.7
provides a urea clearance in the 70 to 80 ml/min range. Prelimi- m2 and standard dialysis tubing, were used. The hemo-
nary data from an ongoing clinical trial demonstrate the safety,
filter and blood lines were changed every 24 to 36 hoursefficiency, and simplicity of the treatment.
or more frequently according to clinical circumstances.
Dialysate was produced online using acid and bicarbon-
ate concentrate and tap water treated with activatedAcute renal failure (ARF) in critically ill patients has a
charcoal and reverse osmosis (RO). Dialysate was en-high mortality. Repeated episodes of hypotension during
riched with potassium to give a final concentration of 4intermittent hemodialysis (IHD) and the blood–dialyzer
mEq/liter. The calcium concentration was 2.5 mEq/liter,membrane interaction with complement and leukocyte
and the glucose concentration was 2 g/liter. The dialysateactivation can further injure the kidneys and delay recov-
bicarbonate concentration was adjusted to between 25ery from ARF [1, 2]. Recent research has focused on
and 35 mEq/liter, depending on the acid-base status ofwhether the dialysis dose, biocompatible membranes,
the patient. Electrolytes, including calcium, phospho-continuous renal replacement therapy (CRRT), or bicar-
rous, and magnesium, were checked every six hours.bonate dialysate have an impact on morbidity and mor-
Heparin was used for anticoagulation and was titratedtality in ARF [3].
to achieve a partial thromboplastin time (PTT) of twiceStudies indicate that the dialysis dose significantly af-
the control level. Phosphate and magnesium were re-fects survival rate in ARF [4] and that bicarbonate dialy-
placed as needed, and parenteral nutrition was adjustedsate improves acid-base balance during CRRT [5]. Based
to compensate for amino acid losses in the dialysate.on these observations, we decided to use slow continuous
The system was set up by the nephrology staff, whodialysis (SCD) to treat ARF patients. The method com-
also initiated and discontinued the treatment. The inten-bines the advantages of traditional continuous venove-
sive care unit nursing staff was trained to monitor thenous hemodialysis (CVVHD), which are gradual solute
treatment, adjust ultrafiltration rate, handle routineand volume removal and improved hemodynamic stabil-
alarms, watch for clotting, and perform saline flushesity, with the advantages of IHD, which are high urea
(used when anticoagulation was contraindicated).clearance, precise ultrafiltration control, and bicarbonate
dialysate.
PRELIMINARY CLINICAL DATA
Slow continuous dialysis with the 2008H machine hasKey words: dialysis dose, slow continuous dialysis, CRRT, urea clear-
ance, acute renal failure. been under evaluation for the past 15 months in an ongo-
ing clinical trial. As of this writing, over 30 critically ill 1999 by the International Society of Nephrology
S-20
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Table 1. Comparison of different renal replacement modalitiespatients with acute and chronic renal failure (CRF) have
for ARF
been treated. Preliminary results from this center have
IHD SCD CRRTbeen reported elsewhere (abstract; Amerling et al, J Am
Blood flow ml/min 200–300 100–300 100–200Soc Nephrol 9:166A, 1998). Of the first 23 patients, 20
Dialysate flow ml/min 500–800 100 15–35patients had oliguric ARF and three had complicated
Dialysate buffer bicarbonate bicarbonate lactate
CRF. Causes of ARF were postcardiac surgery acute Daily urea clearance liters 36 80–90a 20–40c
Daily Kt/V 1.1 2.4b 0.9–1.4tubular necrosis (ATN) in 10 patients, sepsis in three
Weekly Kt/V 7.5 16.8b 6–10patients, cardiogenic shock in two patients, liver failure
Daily dialysate cost (US$) 6 10d 50–100d
in three patients, pancreatitis in one patient, and gastro-
Abbreviations are: IHD, daily intermittent hemodialysis with a dialyzer ureaintestinal bleeding in one patient. The mean treatment clearance of 175 ml/min [7]; SCD, slow continuous dialysis; CRRT, continuous
renal replacement therapytime was 58 (range 12 to 144) hours. Fluid removal was
a Calculated for 24 hr treatmentvaried according to the clinical circumstances and aver- b Assuming urea clearance 60 ml/min and V of 36 liters
c Daily urea clearance is slightly lower than dialysate flow to account for downaged 5.8 6 1.7 liters. No replacement fluid was used. The
timemetabolic control achieved during SCD was excellent, as d From abstract; Martin et al, Blood Purif 17:19, 1999, calculated for 24 hr
treatmentjudged by serum levels of potassium, blood urea nitro-
gen, creatinine, and phosphorus. Acid-base balance was
maintained throughout the treatment. Treatment was
stopped after 48 and 72 hours because of frequent clot-
ate interruptions (clotting, interventions) and still pro-ting in two patients who were treated with F8 mem-
vide excellent dialysis. Some centers perform SCD forbranes. Thirteen patients survived over 30-days post-
8 to 12 hours during the day or night to avoid nighttimetreatment, 11 of whom went home. Of these 11, eight
troubleshooting of the dialysis circuit or, conversely, torecovered renal function. Thus, 30-day survival was 57%,
allow unrestricted access to the patient during the dayand longer-term survival was 48%. Because the treat-
(abstracts; Marshall et al, Blood Purif 17:24, 1999; andment was provided mainly to those patients judged to be
Hu et al, Blood Purif 17:15, 1999).too ill or unstable for intermittent hemodialysis (IHD),
According to Leblanc, Bonnardeaux, and Cardinal,these results are impressive.
CAVHD with a dialysate flow of 4 liter/hr yields a dailyNursing acceptance was high, as the procedure was
Kt/V of 2.0, or 14 per week, assuming nonstop therapyless labor intensive than traditional CRRT. Alarms (low
[7]. Shaver et al. used a 12-hour daily SCD to achieve atransmembrane pressure [TMP], conductivity) occurred
mean Kt/V of 1.64 per treatment (abstract; Shaver etrelatively infrequently and were easily resolved by the
al, Blood Purif 17:31, 1999). In our experience, SCDintensive care unit nursing personnel.
delivered over 24 hours provided a daily Kt/V of 2.4
(16.8 weekly), assuming a urea clearance of 60 ml/min
UREA CLEARANCE and a volume of 36 liters. This compares favorably to
Slow continuous dialysis provides superior small sol- other continuous or intermittent therapies, which deliver
ute clearance compared with other continuous renal re- a weekly Kt/V of 6.2 (for low flow CRRT) or 7.5 (for
placement therapies or IHD. Because the blood flow daily IHD [7] (Table 1).
during conventional CVVHD is very much greater than This may be clinically important, as Tapolyai et al
the dialysate flow (QB 5 100 ml/min, QD 5 16 to 25 ml/ observed an inverse correlation between Kt/V and mor-
min), the dialysate is fully saturated with urea. Thus, the tality rate in 58 critically ill patients treated with IHD
urea clearance in CVVHD equals the dialysate flow rate (abstract; Tapolyai et al, J Am Soc Nephrol 5:530, 1994).
plus the ultrafiltration rate. Roughly, 24 to 30 liters of More recent data from the same group showed that the
plasma are typically cleared per day during CVVHD. If dialysis dose has a strong influence on survival in patients
the dialysate flow is increased to 4 liter/hr, urea clearance with moderate severity scores, independent of the man-
increases to 3 liter/hr, as the dialysate is not completely ner with which the dialysis dose was provided (IHD vs.
saturated at higher dialysate flow rates [6]. SCD using CRRT) [4]. The available data suggest that a daily Kt/V
the F40 dialyzer with a QD of 6 liter/hr (100 ml/min) and for urea of .1.0 is required to achieve a significant im-
a QB of 100 to 300 ml/min provides urea clearance of at pact on mortality [8].
least .3.5 liter/hr (.84 liter/day). We simultaneously
measured blood and dialysate urea nitrogen concentra-
ANTICOAGULATION AND CLOTTINGtions to determine the extraction ratio for SCD in several
Preliminary data from Hu et al suggest that SCD maypatients. Results ranged from 0.6 to 0.9. Thus, urea clear-
be superior to CVVH with regards to clotting and hepa-ances may be as high as 90 ml/min (130 liter/day) in
rin requirement (900 units/hr for SCD vs. 1200 units/hrsome patients.
Because of the higher clearance, SCD can better toler- for CVVH; abstract; Hu et al, Blood Purif 17:15, 1999).
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However, SCD ran for only eight hours daily. Golper et cost and nursing workload (abstracts; Hall et al, Blood
Purif 17:30, 1999; Merz et al, Blood Purif 17:52, 1999;al observed clotting during 12-hour SCD treatments,
with an F8 dialyzer in 3 of 13 treatments (abstract; Cha- and Martin et al, Blood Purif 17:19, 1999). Access to tap
water and the availability of a RO unit are essential.toth et al, Blood Purif 17:16, 1999). Our experience sug-
gests that large surface area dialyzers might not be ad- Depending on the quality of the tap water, water pre-
treatment may be required to achieve Association forvantageous, as both of our patients who were treated
with the F8 dialyzer (surface area of 1.8 m2) experienced the Advancement of Medical Instrumentation (AMII)
standard water quality.frequent clotting. This prompted us to switch to the
smaller F40 dialyzer (surface area of 0.7 m2). Contamination of the dialysate with endotoxins is an-
other potential hazard. Meticulous cleaning of the ma-
chine and the water purification system every 24 to 48
HEMODYNAMIC STABILITY hours can minimize this risk. To add an extra level of
Hu et al compared the hemodynamic stability of SCD safety, the dialysate can be filtered through a dialysate
(N 5 5) and CVVH (N 5 2; abstract; Hu et al, Blood filter (for example, Diasafet; Fresenius Medical Care).
Purif 17:15, 1999). Mean arterial pressure, hypotensive This will ensure the production of ultrapure dialysate
episodes, and vasopressor requirements were compara- with microbial counts ,1 CFU/ml and endotoxin con-
ble in both groups. Golper et al performed SCD in six centration ,0.06 IU/ml [16].
critically ill patients who had failed conventional hemo-
dialysis because of hypotension (abstract; Chatoth et al,
SUMMARYBlood Purif 17:16, 1999). The 12-hour SCD treatments
To our knowledge, this is the first description of thewere hemodynamically well tolerated, but 2 of 13 treat-
use of SCD with a modified hemodialysis machine forments were terminated because of hypotension.
ARF in critically ill patients. SCD is defined by the fol-
lowing parameters: (a) QB 5 100 to 300 ml/min, (b)
ONLINE PRODUCTION OF BICARBONATE QD 5 100 to 300 ml/min, (c) utilization of a modified
BUFFERED DIALYSATE hemodialysis machine with controlled ultrafiltration and
online production of bicarbonate-based dialysate, (d)Slow continuous dialysis uses bicarbonate-buffered di-
continuous or daily treatment for at least 8 to 12 hours.alysate, whereas in the United States, CVVHD is tradi-
Slow continuous dialysis provides a sustained high ratetionally performed using lactate-buffered peritoneal di-
of solute clearance in the range of 70 to 80 ml/min.alysis fluid as the dialysate. The use of the latter is
Possible clinical advantages of this technique are beingproblematic. First, the high glucose concentration in
evaluated in an ongoing clinical trial. Preliminary dataperitoneal dialysate may produce hyperglycemia [9]. Sec-
demonstrate the safety, efficiency, and simplicity of theond, these solutions contain lactate in concentrations of
treatment.35 to 45 mmol/liter in order to compensate for bicarbon-
ate losses in the filtrate. Under physiological conditions,
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